|
|
 |
|
Viewing report
|
|
|
|
Product Profiles: Targeted Cancer Therapies - Trend towards personalized medicine will lead to market fragmentation
Datamonitor, Nov 2011, Pages: 166
The targeted therapies class boasts several of the top-selling anticancer brands, and has fueled most of the recent rapid growth of the oncology market as a whole. In the next decade, several blockbuster targeted therapies will undergo patent expiries and the market will become more fragmented as new targeted therapies are developed for niche populations.
Features and benefits
- Includes targeted cancer therapy drug profiles and development overviews detailing the companies involved and the clinical data that led to approvals
- Includes SWOT analysis of each brand in the targeted cancer therapies class
- Overview of each brand’s positioning in its marketed indications relative to its competitors and in terms of its ability to meet unmet needs
- Analysis of the clinical and commercial attractiveness of the targeted cancer therapies
Highlights
As a growing number of companies strive to develop targeted cancer therapies, competition will inevitably become more intense as more agents in this class reach the market. In addition, increasing pharmacoeconomic pressures will dampen sales growth of drugs in this market as they tend to command a high price.
In recent years an improved understanding of the heterogeneity of cancer tumors and their molecular pathogenesis has led to the development of targeted therapies designed to treat niche subsets of patients with specific genetic mutations.
The co-development of companion diagnostics that can identify the patients that will most benefit from cancer treatment will become increasingly important for developers seeking approval of targeted therapies and the treatment of cancer will become more personalized
Your key questions answered
- Access detailed information about the drugs that make up the most lucrative class in the oncology market
- Understand the key factors that led to the success of some targeted cancer therapy brands and the issues which have hindered the uptake of others
- Understand how the targeted cancer therapies market will change in the future as developers target niche indications
|
|
|
|
